Retraction Note: Adiponectin administration alleviates DSS-induced colonic inflammation in Caco-2 cells and mice

Zhao, Qin; Liu, Yang; Tan, Lei; Yan, Liyong; Zuo, Xiuli

doi:10.1007/s00011-022-01564-4

Cited by 2 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Li et al reported that topical application of globular adiponectin improved clinical signs and decreased inflammation in the ocular surface and lacrimal gland in EDE mice [ 6 ]. Besides, several studies have revealed adiponectin’s epithelial cell protective effect [ 24 , 25 , 26 , 27 , 28 ].…”

Section: Discussionmentioning

confidence: 99%

Enhanced Immunomodulation, Anti-Apoptosis, and Improved Tear Dynamics of (PEG)-BHD1028, a Novel Adiponectin Receptor Agonist Peptide, for Treating Dry Eye Disease

et al. 2022

View full text Add to dashboard Cite

Dry eye disease (DED) is characterized by impaired tear dynamics, leading to complex pathophysiological conditions. (PEG)-BHD1028, a peptide agonist to AdipoRs, was evaluated as a potential therapeutic agent for DED based on the reported physiological function of adiponectin, including anti-inflammation and epithelial protection. Therapeutic effects of (PEG)-BHD1028 were evaluated in experimentally induced EDE with 0.001%, 0.01%, and 0.1% (PEG)-BHD1028 in mice and 0.1%, 0.2%, and 0.4% in rabbits for 10 days. In the rabbit study, 0.05% cyclosporine was also tested as a comparator. The results from the mouse study revealed significant improvement in tear volumes, tear breakup time (TBUT), inflammation, and corneal severity score (CSS) within 10 days at all (PEG)-BHD1028 concentrations. In the rabbit study, the tear volume and TBUT significantly increased in (PEG)-BHD1028 groups compared with vehicle and 0.05% cyclosporine groups. The CSS, apoptosis rate, and corneal thickness of all (PEG)-BHD1028 and 0.05% cyclosporine groups were significantly improved relative to the vehicle group. The immune cell counts of 0.2% and 0.4% (PEG)-BHD1028 treated groups were significantly lower than those of the vehicle group. These results represent the potential of (PEG)-BHD1028 as an effective therapeutic agent for DED.

show abstract

Section: Discussionmentioning

confidence: 99%

Enhanced Immunomodulation, Anti-Apoptosis, and Improved Tear Dynamics of (PEG)-BHD1028, a Novel Adiponectin Receptor Agonist Peptide, for Treating Dry Eye Disease

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The complex inflammatory process involves a wide variety of inflammatory cells, molecules, and pathways that contribute to obesity‐linked MetS, NAFLD, arthritis, T2DM, CVD, cancer, etc 14,101–103 . During inflammation, adipocytes become enlarged and inflamed and secrete multiple adipokines (i.e., leptin, resistin, adiponectin, and inflammatory cytokines including TNF‐α, IL‐1, and IL‐6) that have pro‐inflammatory and anti‐inflammatory properties 101,104,105 . Many adipokines such as monocyte chemotactic protein (MCP)‐1, TNF‐α, and IL‐6 have been reported to promote IR via inflammation and metabolic dysfunctions, which is highly deleterious for vascular functions 65,73,106 .…”

Section: Pathophysiology Of Metsmentioning

confidence: 99%

“…14,[101][102][103] During inflammation, adipocytes become enlarged and inflamed and secrete multiple adipokines (i.e., leptin, resistin, adiponectin, and inflammatory cytokines including TNF-α, IL-1, and IL-6) that have pro-inflammatory and anti-inflammatory properties. 101,104,105 Many adipokines such as monocyte chemotactic protein (MCP)-1, TNF-α, and IL-6 have been reported to promote IR via inflammation and metabolic dysfunctions, which is highly deleterious for vascular functions. 65,73,106 In fact, the expression levels of those inflammatory factors, such as (MCP)-1, TNF-α, and IL-6 are upregulated in adipose tissue macrophages, which increase from 10%-15% to 45%-60% with obesity.…”

Section: Chronic Inflammationmentioning

confidence: 99%

“…100 The inflammatory markers induce endothelial dysfunction, myocardial growth, metabolic dysregulation, IR, and NAFLD through the activation of NF-κB and Jak/ STAT and/or Ras/ERK/MAPK signaling cascade (Figure 2). 14,107,108 In contrast, adiponectin, the antiinflammatory cytokine, attenuates inflammatory responses by diminishing the TLR4 signaling pathways in different cell types, 104,109 which consequently improve metabolism, inflammation, atherosclerosis, and CVD. 110,111 Toll-like receptors (TLRs) primarily induce low-grade chronic inflammation and IR by the activation of TLR2 and TLR4 through pathogen-associated molecular patterns (PAMPs), 109 which are enhanced by a leaky or damaged gut.…”

Section: Chronic Inflammationmentioning

confidence: 99%

See 1 more Smart Citation

Dietary carbohydrates: Pathogenesis and potential therapeutic targets to obesity‐associated metabolic syndrome

Akter

Akhter

Chaudhury³

et al. 2022

BioFactors

View full text Add to dashboard Cite

Metabolic syndrome (MetS) is a common feature in obesity, comprising a cluster of abnormalities including abdominal fat accumulation, hyperglycemia, hyperinsulinemia, dyslipidemia, and hypertension, leading to diabetes and cardiovascular diseases (CVD). Intake of carbohydrates (CHO), particularly a sugary diet that rapidly increases blood glucose, triglycerides, and blood pressure levels is the predominant determining factor of MetS. Complex CHO, on the other hand, are a stable source of energy taking a longer time to digest. In particular, resistant starch (RS) or soluble fiber is an excellent source of prebiotics, which alter the gut microbial composition, which in turn improves metabolic control. Altering maternal CHO intake during pregnancy may result in the child developing MetS. Furthermore, lifestyle factors such as physical inactivity in combination with dietary habits may synergistically influence gene expression by modulating genetic and epigenetic regulators transforming childhood obesity into adolescent metabolic disorders. This review summarizes the common pathophysiology of MetS in connection with the nature of CHO, intrauterine nutrition, genetic predisposition, lifestyle factors, and advanced treatment approaches; it also emphasizes how dietary CHO may act as a key element in the pathogenesis and future therapeutic targets of obesity and MetS.

show abstract

Retraction Note: Adiponectin administration alleviates DSS-induced colonic inflammation in Caco-2 cells and mice

Cited by 2 publications

References 0 publications

Enhanced Immunomodulation, Anti-Apoptosis, and Improved Tear Dynamics of (PEG)-BHD1028, a Novel Adiponectin Receptor Agonist Peptide, for Treating Dry Eye Disease

Enhanced Immunomodulation, Anti-Apoptosis, and Improved Tear Dynamics of (PEG)-BHD1028, a Novel Adiponectin Receptor Agonist Peptide, for Treating Dry Eye Disease

Dietary carbohydrates: Pathogenesis and potential therapeutic targets to obesity‐associated metabolic syndrome

Contact Info

Product

Resources

About